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mobility of the COMP digested fragment. In addition, EDTA chela- 
tor totally abolished the enzymatic activity. Take together; Zinc is 
essential for the ADAMTS7-mediated COMP degradation. 
Cleavage of COMP by ADAMTS-7 is pH-dependent- ADAMTS- 
7 generated the largest amount of COMP fragments in the range 
of physiological pH (pH 7.5) up to pH 9.5, whereas the enzyme 
did not produce visible COMP fragments when pH values lower 
than 6.5 or higher than 10.5, indicating that the digestive activity 
of ADAMTS-7 is also pH-dependent. 
Increased expression of ADAMTS-7 in the cartilage and syn- 
ovium of patients with rheumatoid arthritis - To determine 
whether the expression of ADAMTS-7 in cartilage and synovium 
is altered in OA and/or RA, a real-time PCR was performed. 
ADAMTS-7 mRNA was significantly upregulated in RA cartilage, 
and only slightly upregulated in OA cartilage, compared to the 
normal control. Further analysis of synovium samples revealed 
that the level of ADAMTS-7 was also significantly upregulated in 
RA synovium compared to normal synovium. 
Conclusion: ADAMTS-7 digests COMP in a Zn 2+- and pH- 
dependent manner. ADAMTS-7 is significantly upregulated in car- 
tilage and synovium obtained from patients with RA, suggesting 
that ADAMTS-7 plays an important role in joint degenerative dis- 
ease progression. 
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Most drugs inhibiting bone resorption used in the treatment of 
osteoporosis decrease excretion of cartilage degradation mark- 
ers and some of them stimulate chondrocytes and showed a pro- 
tective effect on experimental arthropathies in animals. Among 
them, estrogens and raloxifene (RLX), SERM group, not only in- 
hibit bone resorption but also act receptively on chondrocytes. 
Estrogens and HRT retarded progress of knee osteoarthritis but 
there is no evidence concerning a similar effect of RLX. In our par- 
allely published work, there were statistically significant improve- 
ment of mean of WOMAC index which corelated with decrease of 
CTX-II excretion. 
The aim of the study was to evaluate the effect of the 12-month- 
therapy with RLX in middle-aged women with knee osteoarthri- 
tis (OAK) and osteopenia on cartilage degeneration and bone 
turnovers markers. 
The study was conducted in 65 women, aged 52-79, mean 65.4 
years, with diagnosed OAK according to ACR criteria and rated 
on a 3-point Kellgren - Lawrence scale, with low bone mass (BMD 
of Hip neck and/or L1-L4 vertebrae T-score between -1.0 and - 
2.5), without contraindications to be treated with RLX. Patients 
were randomly assigned in the approximate ratio 1:2 to the con- 
trol (C), or to group (E) being treated for 12 mounts with 60 mg of 
RLX p.o. per day. All the participants took Calcium up to 1200 
mg/d plus 800 IU Vit. D3 and Tramadol 1-2 x 50mg/24 hours 
in the case of pain. The evaluation of RLX effect on joint car- 
tilage was based on measurements of excreted with urine the 
cartilage-specific C-terminal tetrapeptide of type II collagen CTX- 
II/Cr and cartilage oligometric matrix protein (COMP) with ELISA 
method. The bone turnover was monitored with bone-specific al- 
kaline phosphatase (b-ALP), osteoprotegerin (OP), bone-specific 
C-terminal tetrapeptide of type I collagen (CTX-I), and soluble 
NF-kappa-B receptor activator (sRANKL) with ELISA method. 
The patients and markers were monitored before and after 3, 6, 
and 12 months of treatment with RLX. 
Results: Regressive analysis of time changes showed statisti- 
cally significant decrease in OP, CTX-II, CTX-II/Cr in the group 
treated with RLX and lack of any marker changes in the con- 
trol group. The drop of excreted CTX-II and CTX-II/Cr after 12 
months in group E was 30% and 40%, respectively with regard to 
the values before the treatment. There were neither differences 
in time and between the groups E and C as for markers of bone 
metabolism nor their correlation with markers of cartilage degen- 
eration nor COMP changes. 
Conclusion: We observed a statistically significant decrease 
in CTX-II and CTX-II/Cr excretion (with simultaneous ignificant 
lowering of WOAC index) in patients treated with RLX as com- 
pared to lack of such changes in the control group. It seems that 
RLX has a curative effect on cartilage degradation with improve- 
ment of clinical outcomes. There was no evidence on interaction 
between cartilage and bone metabolismexcept of decrease of OP. 
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Background: Collagen induced arthritis in the rat has been ex- 
tensively studied as a model of rheumatoid arthritis (RA). Dis- 
ease activity and structural joint damage can be quantitatively as- 
sessed, and in addition biochemical markers have been adopted 
in the monitoring of disease progression in the CIA model. Helical 
fragments of type II collagen (C2C), which are generated by the 
action of aggrecanase, are slightly increased in the CIA model 
(Mayer et al, JBMR 2004;19:SA030). However, other proteases 
participating in the degradation of articular cartilage give rise to 
other collagen fragments, and therefore the present study was 
undertaken to investigate if fragments of C-telopeptide of type II 
collagen (CTX II) in circulation could reflect disease activity in this 
animal model of RA. 
Objective: To investigate the time-course of collagen type II 
degradation in circulation in the CIA model of rheumatoid arthrti- 
tis. 
Methods: Twenty, 6-week old female Lewis (LEW/SsN/CrCrlBR) 
rats were randomized into 2 groups: (I) CIA group (15 animals) 
and (11) negative control (5 animals). The immunization was 
performed once at Day 1 with porcine type II collagen. Blood 
samples were collected at day 1 (prior to immunization), 8, 15, 
18 and 23, and in addition, lavage synoviocentesis was per- 
formed at study termination. Cartilage degradation was evalu- 
ated using serum CTX-II (Nordic Bioscience, Denmark) and C2C 
(Ibex, Canada) assays. Bone resorption was estimated by CTX-I 
(Nordic Bioscience, Denmark). Paw inflammation was assessed 
semi-quantitatively using scores from 0 to 5. 
Results: CIA group developed arthritis at Day 15 after immuniza- 
tion. The cumulative macroscopic scores from tarsal and carpal 
joints (left and right) were 0.0 and 9.1 4- 1.6 (p = 0.0012) in neg- 
ative and CIA groups, respectively. Serum CTX II levels were in- 
creased 295% compared to controls at Day 15 (p = 0.0012). C2C 
was increased 12% in the CIA group, which, however, did not 
reach statistical significance. The cumulative macroscopic scores 
